A prospective, observational, multicenter study of safety and effectiveness of the fixed-ratio combination (FRC) of insulin glargine 100 U/mL and lixisenatide (iGlarLixi) in people with T2D who fast during Ramadan
Latest Information Update: 10 May 2021
At a glance
- Drugs Insulin-glargine/lixisenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SOLIRAM
- 10 May 2021 New trial record
- 23 Mar 2021 Interim results (n=155) of participants who fasted during Ramadan in 2020 (Wave 1), presented at the 103rd Annual Meeting of the Endocrine Society.